

EXPEDITING DISCOVERY AND DEVELOPMENT

How did Mindbreeze help a pharmaceutical company speed up time to market by 50%?

Mindbreeze's intelligent document processing and knowledge extraction capabilities streamlined processes for a major pharmaceutical organization – fast research, more knowledge, and informed decision-making.

PROBLEM

Life science organizations often face challenges managing and utilizing their data effectively to make quicker and more informed decisions. Access to scattered data across various systems makes it practically impossible for researchers and authorities to make life-changing discoveries in a highly regulated industry.

This organization had:

- 6,500 different product categories
- More than 17,000 employees (all needing critical information)
- Millions of indexed documents

The organization needed to analyze clinical trial data, drug information, and review applications faster and more consistently.

SOLUTION

Mindbreeze indexed existing internal data (from Documentum, such as action letters, review recommendations, and information requests) and external data (such as eCTD backbone: forms, trial data) and linked it with structured data from the Oracle database.

AI Features Used:

- **Search-driven analytics** for autosuggestions based on user search history, popular queries, and document keywords
- **Entity Recognition Service** for automatic extraction of necessary information from large documents and datasets.
- **Semantic Relations Service** to identify and extract correlations of existing information and provide relevant results on a priority basis.

Data Sources:

- Internal data from Documentum, an enterprise content management system
- External data from trials and medical forms
- Oracle Database

IMPACT

- Free data from siloed, legacy infrastructures
- Swiftly identify and address inquiries
- Get drugs to reach the market and improve patient well-being WAY FASTER!

With Mindbreeze, the company was able to improve and speed up time to market by 50%.

The screenshot displays the Mindbreeze web application interface. On the left, there is a search bar with 'Fluoxetine' entered and a navigation menu with options like 'EVERYTHING', 'IND', 'NDA', 'ANDA', 'DOCUMENTS', and 'REVIEWER'. Below the search bar, there are filters for 'LABELER NAME', 'DOSAGE FORM', and 'BRAND NAME'. The main area shows search results for 'About 101 Results', listing various drug combinations like 'Olanzapine and Fluoxetine' and 'Fluoxetine' alone, with details on drug name, company, ingredient, and application number.

On the right, a detailed view for 'DRUG 360: NDA018936 - Prozac' is shown. It includes information about the company (Dista Products Company), original/tentative approvals (20211231), and a table of products. The table lists 'Prozac' with different strengths (20 mg, 10 mg, 40 mg, 20 mg) and forms (CAPSULE), all from Dista Products Company, except for the 20 mg CAPSULE which is from REMEDYREPACK INC.

Below the table, there is a 'Similar Applications' section featuring a radar chart. The chart compares performance characteristics between a new submission and an existing approved drug across five categories: Sexual dysfunction, Discontinuation syndrome, Pregnancy, Suicide, and QT prolongation. The chart shows multiple data series represented by different colored lines, indicating varying levels of performance or risk for each characteristic.

Comparison of performance characteristics between a new submission and an existing approved drug